Patent issuance expands U.S. patent portfolio for AVERSA™ transdermal abuse deterrent technology

专利发行扩大了美国专利组合的厌恶™ 透皮滥用威慑技术

ORLANDO, FL / ACCESSWIRE / September 20, 2023 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced that the United States Patent and Trademark Office (USPTO) has granted US Patent No. 11,759,431 for Nutriband's proprietary AVERSA™ abuse deterrent technology utilizing taste aversion to address the primary routes of abuse of opioid based transdermal patches..

佛罗里达州奥兰多/ACCESSWIRE/2023年9月20日/透皮药品开发商Nutriband Inc.（纳斯达克股票代码：NTRB）（纳斯达克股票代码：NTRBW）今天宣布，美国专利商标局（USPTO）已授予美国专利Nutriband专有的AVERSA编号11759431™ 滥用威慑技术利用味觉厌恶来解决滥用阿片类药物透皮贴剂的主要途径。。

The issuance of this patent, entitled, 'Abuse and Misuse Deterrent Transdermal Systems,' further expands Nutriband's intellectual property protection in the United States for its portfolio of abuse deterrent transdermal products based on its proprietary AVERSA™ abuse deterrent technology. This technology can be incorporated into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential.

这项名为“滥用和滥用威慑透皮系统”的专利的发布进一步扩大了Nutriband在美国的知识产权保护，因为它基于其专有的厌恶情绪，其滥用威慑透皮产品组合™ 滥用威慑技术。该技术可以掺入透皮贴剂中，以防止滥用，转移，滥用和意外暴露具有滥用潜力的药物。

Nutriband's lead product under development is AVERSA™ Fentanyl, an abuse deterrent fentanyl transdermal system, with the potential to become the first abuse deterrent pain patch on the market. AVERSA™ Fentanyl is estimated to have the potential to reach peak annual U.S. sales of $80M - $200M.1.

Nutriband正在开发的主导产品是厌恶的™ 芬太尼是一种滥用威慑芬太尼透皮系统，有可能成为市场上第一个滥用威慑疼痛贴剂。厌恶™ 据估计，芬太尼有可能达到每年美国最高销售额8000万美元至2亿美元。

'The issuance of this patent covering our AVERSA™abuse deterrent transdermal technology that utilizes taste aversion to address a primary route of abuse of opioid patches is an important component of our global IP portfolio.' stated Gareth Sheridan, Nutriband CEO. 'This new patent strengthens our intellectual property position, which includes patents issued in 45 countries around the world.'.

'这项专利的发布涵盖了我们的厌恶™滥用威慑透皮技术利用味觉厌恶来解决滥用阿片类药物贴剂的主要途径，是我们全球知识产权组合的重要组成部分Nutriband首席执行官Gareth Sheridan说这项新专利加强了我们的知识产权地位，其中包括全球45个国家的专利。

1 Health Advances market analysis report 2022

1健康进展市场分析报告2022

About AVERSA™ Technology

关于厌恶™ 技术

Nutriband's AVERSA™ abuse deterrent transdermal technology can be utilized to incorporate aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. The AVERSA™ abuse deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl while making sure that these drugs remain accessible to those patients who really need them.

Nutriband的厌恶™ 滥用威慑透皮技术可用于将厌恶剂掺入透皮贴剂中，以防止滥用，转移，滥用和意外暴露具有滥用潜力的药物。厌恶™ 滥用威慑技术有可能改善易受滥用的透皮药物（如芬太尼）的安全性，同时确保真正需要这些药物的患者能够接触到这些药物。

The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, Canada, Mexico, and Australia..

该技术涵盖了广泛的知识产权组合，其中包含在美国，欧洲，日本，韩国，俄罗斯，加拿大，墨西哥和澳大利亚授予的专利。。

About Nutriband Inc.

关于Nutriband股份有限公司。

We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential..

我们主要从事透皮药品组合的开发。我们正在开发的主要产品是包含我们厌恶的滥用威慑芬太尼贴剂™ 滥用威慑技术。厌恶™ 技术可以纳入任何透皮贴剂中，以防止滥用，滥用，转移和意外暴露具有滥用潜力的药物。。

The Company's website is www.nutriband.com. Any material contained in or derived from the Company's websites, or any other website is not part of this press release.

本公司的网站是www.nutriband.com。本公司网站中包含或派生的任何材料，或任何其他网站不属于本新闻稿的一部分。

Forward-Looking Statements

前瞻性声明

Certain statements contained in this press release, including, without limitation, statements containing the words ‘'believes,' 'anticipates,' 'expects' and words of similar import, constitute 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties.

本新闻稿中包含的某些陈述，包括但不限于包含“相信”，“预期”，“期望”和类似进口词语的陈述，构成了私人含义范围内的“前瞻性陈述”1995年证券诉讼改革法案。这种前瞻性陈述涉及已知和未知的风险和不确定性。

The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company's ability to develop its proposed abuse deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company's business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operations' in the Company's Form S-1, Form 10-K for the year ended January 31, 2020 and Forms 10-Q, and the Company's other filing.

由于多种因素，包括公司开发拟议的滥用威慑芬太尼透皮系统和其他拟议产品的能力，获得专利保护的能力等因素，本公司的实际结果可能与其前瞻性声明中预期的结果大不相同为其滥用技术，其获得开发产品和进行必要临床试验所需资金的能力，获得联邦食品和药物管理局批准销售其可能在美国开发的任何产品的能力，以及获得任何其他必要的监管批准以销售任何产品在其他国家，包括欧洲国家，其销售其可能开发的任何产品的能力，创建，维持，管理或预测其增长的能力；吸引和留住关键人员的能力；公司业务战略或发展计划的变化；竞争；业务中断；不利宣传以及通常与资本不足的发展中公司有关的国际，国家和地方一般经济和市场状况和风险，以及“风险因素”和“管理层对财务状况和运营结果的讨论和分析”中包含的风险公司的表格s-1，截至1月31日的年份的表格10-K，2020年并形成10-Q，以及公司的其他归档。

For more information, contact:

欲了解更多信息，请联系：

Patrick Ryan

帕特里克·瑞安

CTO Nutriband Inc

CTO Nutriband公司

paddyr@nutriband.com / support@nutriband.com

paddyr@nutriband.com哦，是的support@nutriband.com

121 S Orange Ave, Orlando, FL, 32407

121 S Orange Ave，佛罗里达州奥兰多，32407

+1 (407) 377-6695

+1 (407) 377-6695

SOURCE: Nutriband, Inc.

来源：Nutriband，Inc。

View source version on accesswire.com:

在AccessWire.com上查看源版本：

https://www.accesswire.com/785775/nutriband-announces-issuance-of-us-patent-for-transdermal-abuse-deterrent-technology

https://www.accesswire.com/785775/nutriband-announces-issuance-of-us-patent-for-transdermal-abuse-deterrent-technology